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RNA-Seq and ChIP-Seq Reveal SQSTM1/p62 as a Key
Mediator of JunB Suppression of NF-jB-Dependent
Inflammation
Xiaoling Zhang1, Jane Y. Jin1, Joseph Wu1, Xiaoxia Qin2, Robert Streilein1, Russell P. Hall1 and
Jennifer Y. Zhang1
Mice with epidermal deletion of JunB transcription factor displayed a psoriasis-like inflammation. The relevance
of these findings to humans and the mechanisms mediating JunB function are not fully understood. Here we
demonstrate that impaired JunB function via gene silencing or overexpression of a dominant negative mutant
increased human keratinocyte cell proliferation but decreased cell barrier function. RNA-seq revealed over 500
genes affected by JunB loss of function, which included the upregulation of an array of proinflammatory
molecules relevant to psoriasis. Among these were tumor necrosis factor a (TNFa), CCL2, CXCL10, IL6R, and
SQSTM1, an adaptor protein involved in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)
activation. Chromatin immunoprecipitation (ChIP)-Seq and gene reporter analyses showed that JunB directly
suppressed SQSTM1 by binding to a consensus AP-1 cis element located around 2kb upstream of SQSTM1-
transcription start site. Similar to JunB loss of function, SQSTM1-overexpression induced TNFa, CCL2, and
CXCL10. Conversely, NF-kB inhibition genetically with a mutant IkBa or pharmacologically with pyrrolidine
dithiocarbamate (PDTC) prevented cytokine, but not IL6R, induction by JunB deficiency. Taken together, our
findings indicate that JunB controls epidermal growth, barrier formation, and proinflammatory responses
through direct and indirect mechanisms, pinpointing SQSTM1 as a key mediator of JunB suppression of NF-kB-
dependent inflammation.
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INTRODUCTION
Psoriasis and psoriatic arthritis affect nearly 3% of the US
population (Helmick et al., 2014; Rachakonda et al., 2014).
Although the etiology of the process is known to be multifold
involving multiple cell types and various genetic and
environmental factors, it is clear that a disarrayed T-cell-
driven immune response is critical for the pathogenesis of
psoriasis (Clark, 2010). Current therapies are mostly designed
to target immune cells, and the treatment results are often
mixed and unpredictable (Belge et al., 2014). Recently, it has
become apparent that defects in epidermal cells, the predo-
minant barrier cells of the skin, can initiate a wide spectrum of
immune responses. This was best demonstrated using condi-
tional genetic animal models. Of particular interest, mice with
epidermal deletion of JunB, an AP-1 family transcription
factor, alone or together with c-Jun, developed joint and
skin lesions that bared a remarkable resemblance to human
arthritis and psoriasis, respectively (Zenz et al., 2005). In
addition, targeted JunB deletion in epidermal cells led to a
multiorgan inflammation involving blood, kidney, and lymph
nodes (Meixner et al., 2008). These studies establish that JunB
has an important role in epidermal cell–mediated innate and
adaptive immune responses in mice.
In humans, JunB is located in the previously identified
psoriasis susceptibility locus PSOR6 (19p13; Huffmeier et al.,
2009), although the significance of which has not been
validated by later genome-wide association study studies.
Interestingly, JunB mRNA levels were found to be increased
in psoriatic lesions as compared with nonlesional skin
(Johansen et al., 2004; Kulski et al., 2005; Haider et al.,
2006), whereas JunB protein levels were reduced in the basal
and spinous layers of the lesional epidermis (Zenz et al., 2005;
Park et al., 2009). The discrepancy between the mRNA and
protein levels may be due to the presence of lymphocytes in
the lesional skin or by a posttranslational effect. Regardless,
the reduced protein expression suggests that JunB-hypo-
function in epidermal cells may have a causal effect on
ORIGINAL ARTICLE
1Department of Dermatology, Duke University, Durham, North Carolina, USA
and 2Genome Sequencing & Analysis Core Resource, Duke University,
Durham, North Carolina, USA
Correspondence: Jennifer Y. Zhang, Department of Dermatology, Duke
University, 40 Duke Medicine, Duke. S. Purple Zone, Rm 4032B, DUMC3135,
Duke University Medical School, Durham, North Carolina 27710, USA.
E-mail: jennifer.zhang@duke.edu
Received 14 September 2014; revised 26 November 2014; accepted 4
December 2014; accepted article preview online 16 December 2014;
published online 15 January 2015
Abbreviations: ChIP, chromatin immunoprecipitation; DNJunB, deletion
mutant of JunB; NF-kB, nuclear factor kappa-light-chain-enhancer of activated
B cell; RT–PCR, reverse transcriptase–PCR; TER, transepithelial electrical
resistance; TNFa, tumor necrosis factor
1016 Journal of Investigative Dermatology (2015), Volume 135 & 2015 The Society for Investigative Dermatology
epidermal cell proliferation and inflammation. In agreement
with this possibility, our recent studies have shown that JunB
inhibits, whereas its dominant negative mutant promotes,
epidermal growth (Jin et al., 2011).
In this study, we demonstrated that gene silencing of JunB
in normal epidermal cells resulted in an increased cell
proliferation and compromised epidermal barrier function.
By using global RNA-seq and chromatin immunoprecipitation
(ChIP)-seq, we found that JunB regulated expression of a wide
range of molecules involved in cell growth, interaction,
differentiation, and inflammation through both direct and
indirect mechanisms. In particular, JunB directly interacted
with the consensus AP-1 response element to suppress gene
transcription of SQSTM1/p62, an adaptor protein linked to
Paget’s disease of bone and neurodegenerative disorders, and
is also upregulated in psoriasis (Sundaram et al., 2011; Rea
et al., 2014). SQSTM1/p62 has been characterized as a key
regulator involved in nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) activation and auto-
phagy (Wooten et al., 2005; Zotti et al., 2014). We found that
NF-kB, but not autophagy, is essential for the expression
of various psoriasis-relevant chemokines induced by the
decreased JunB function. These findings demonstrate that
JunB-hypofunction impairs epidermal barrier function, and
triggers a proinflammatory response through direct and
indirect target gene regulation, and identified SQSTM1 and
NF-kB signaling axis as a potential therapeutic target for skin
diseases such as psoriasis.
RESULTS
JunB loss of function leads to an increased keratinocyte cell
proliferation but reduced barrier function
To determine the role of JunB in human skin, we first
examined JunB loss of function effects on epidermal growth
and barrier function via small interfering RNA-mediated gene
silencing in primary human keratinocytes. The efficiency of
gene silencing was confirmed by reverse transcriptase–PCR
(RT–PCR) and western blotting (Figure 1a). Cell growth
analyses were performed in the absence or presence of tumor
necrosis factor a (TNFa), which has been shown to inhibit
normal keratinocyte growth in culture (Detmar and Orfanos,
1990). JunB gene silencing induced a significantly higher rate
of cell proliferation and diminished the growth inhibitory
effects of TNFa (Figure 1b). To assess the effects on barrier
function, we plated cells on permeable membrane inserts for
the induction of differentiation with 1.2 mM Caþ þ and then
measured the transepithelial electrical resistance (TER) as
described (Sumigray et al., 2012). A higher TER value corres-
ponds to a healthier barrier function. Gene silencing of JunB
significantly reduced the TER at both the 24 and 48 hour time
points (Figure 1c), indicating that JunB is important for the
epidermal cell barrier formation.
To confirm the growth effects observed with gene silencing,
we transduced keratinocytes with retrovirus for the stable
overexpression of JunB or the dominant negative deletion
mutant of JunB (DNJunB; Figure 1d). Monolayer cell growth
analysis revealed that the overexpression of JunB significantly
reduced cell proliferation, whereas DNJunB induced a modest
increase in cell growth (Figure 1e). Consistently, skin grafts
regenerated on severe combined immunodeficient mice with
the transduced keratinocytes showed that JunB reduced
epidermal proliferation, whereas DNJunB induced hyperpro-
liferation as indicated by the over 2-fold changes of the
number of Ki-67-positive cells (Figure 1f). These findings
indicate that JunB is involved in controlling epidermal cell
proliferation and barrier function.
Global RNA-seq analysis reveals an important role for JunB in
the regulation of epidermal inflammation and cell adhesion
To examine how JunB regulates epidermal homeostasis, we
performed RNA-seq with mRNA isolated from primary human
keratinocytes that had been transfected with small interfering
RNA oligonucleotides for JunB gene silencing. Around 8–20
million sequence reads passed the quality control for each
sample, accounting for over 15,000 genes that were expressed
at a detectable level in normal human keratinocytes. In
response to JunB gene silencing, about 500 genes displayed
significant changes with 138 decreased and 84 increased by
over 2-fold (Supplementary Table S1–S2 online). The JunB-
responsive genes include many of those involved in inflam-
mation and cell adhesion as shown by the heat-map analysis
(Figure 2a–b). Of the 29 inflammation-related genes, over
70% of them were found to be increased in patient psoriatic
lesions in a recent large-scale RNA-seq data set (GSE54456; Li
et al., 2014). In addition, a majority of these molecules have
been previously linked to psoriasis and psoriatic arthritis.
These include CCL2, CXCL10, CXCL11, and TNFa, as well
as receptors such as IL6R and the leukocyte interaction
molecule ICAM1(Paukkonen et al., 1995; Fraticelli et al.,
2001; Plant et al., 2006; Antonelli et al., 2009; Danik et al.,
2009). Similarly, 70% of the 16 downregulated cell adhesion
molecules were found to be decreased in patient psoriatic
lesions (GSE54456).
To validate the RNA-seq data, we performed RT–PCR for a
number of proinflammatory molecules, including TNFa,
CXCL10, IL6R, and SQSTM1, which were increased in
response to reduced JunB expression (Figure 2c). To further
examine whether the altered mRNA levels were reflected at
protein levels, we collected conditioned keratinocyte culture
media for cytokine analysis. We found that CCL2 and CXCL10
were significantly upregulated in cells with reduced JunB
expression (Figure 2d). In agreement with the results observed
with gene silencing, the overexpression of the DNJunB also
increased the expression levels of multiple cytokines, such as
TNFa, CXCL10, and CCL2, as demonstrated by RT–PCR or
cytokine analysis (Supplementary Figure S1a–b online). In
addition, we confirmed by RT–PCR that the cell adhesion
molecule CNTN1 was reduced, whereas MMP7, MMP9, and
ICAM1 was upregulated, whereas the terminal differentiation
marker filaggrin was not changed in response to reduced JunB
expression (Supplementary Figure S2a online). Western blot-
ting further validated the increased expression of ICAM1 in
response to JunB gene silencing (Supplementary Figure S2b
online). These results indicate that JunB loss of function
induces cell adhesion defects and proinflammatory responses
reminiscent of psoriasis.
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ChIP-Seq analysis identifies SQSTM1 as a direct JunB target
Next, we performed ChIP-seq analysis to identify JunB direct
target genes. To do this, the genomic DNA was isolated from
primary human keratinocytes for ChIP with an antibody
against JunB and then subjected to ChIP-seq analyses. Peak
calling using Chipseeqer identified a total of 2,377 sequences.
Alignment with the RefSeq database revealed that 43% of
these sequences were located in gene promoter regions, with
17% in the proximal region (2 kb±) and 26% in the distal
region (2–50 kb; Figure 3a). The rest were located in the
introns (32.7%), intergenic regions (20.4%), and exons (0.2%).
Motif analysis with ChipSeeqerFIRE demonstrated that AP-1
consensus elements were present with a high confidence
score of 10 out of 10 (Giannopoulou and Elemento, 2011;
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Figure 1. JunB loss of function leads to increased epidermal cell proliferation and reduced barrier function. (a) Confirmation of gene silencing via real-time
reverse-transcriptase–PCR and western blotting. Relative expression levels of JunB were shown below each band via densitometry. (b) Cell growth of human
keratinocytes treated with or without 50 ng ml 1 TNFa (tumor necrosis factor a) for 72 hours. (c) Barrier functions as measured by the Transepithelial Electrical
Resistance (TER). Keratinocytes were induced to differentiate with 1.2mM Caþ þ on permeable membranes for 24 and 48 hours before TER measurement.
(d) Confirmation of gene expression via immunoblotting. (e) Cell growth analysis. (f) Immunostaining of 6-week-old skin grafts generated on severe combined
immunodeficient mice with human keratinocytes transduced to express genes as indicated. Ki-67 (orange) and nuclei (blue). Graphs represent the average values
of triplicate samplesþ SD. P-values were obtained via a two-tiered Student’s t-test. Con, control; scale bar¼100mm.
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Figure 2. RNA-seq reveals JunB-targets involved in inflammation and cell adhesion. (a, b) Heat-map analysis of gene expression of three independent sets of
human keratinocytes underwent gene transfection with small interfering RNA (siRNA) oligonucelotides targeting JunB (siJunB) or nonsilecning control (siCon).
(c) Real-time RT–PCR for JunB, TNFa, IL6R, CCL2, CXCL10, and SQSTM1. Graph represents average fold changes of triplicate samplesþ SD. (d) Cytokine analysis
of cell culture conditioned media. Graph represents the average of tetrad samplesþ SD. TNFa, tumor necrosis factor a.
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Figure 3b), confirming that JunB ChIP achieved a satisfactory
enrichment of the putative AP-1 target genes.
Focused peak analysis on UCSC genome browser (hg19)
identified a peak on chromosome 5 at B1.8 kb upstream of
the transcription start site of SQSTM1 (Figure 3c), which
encodes an adaptor protein important for NF-kB activation
and autophagy (Sanz et al., 2000), and was recently found
to be upregulated in psoriatic lesions (Lee et al., 2011). In
agreement with SQSTM1 being an actively transcribed gene,
its promoter region was enriched with H3K27Ac modification,
a marker for active enhancers, and DNase-sensitive, an
indicator for open chromatin state. In addition, within the
peak harbored a putative AP-1 response element (TGACTCA)
(Figure 3d). To validate the ChIP-seq result, we performed
quantitative ChIP–PCR with primers designed to cover the
50 and 30 ends of the AP-1 cis element. As expected, JunB
ChIP achieved an over 10-fold enrichment of SQSTM1-
sequence (Figure 3e). To further examine the importance of
the AP-1 cis element, we performed luciferase gene reporter
analysis and found that JunB inhibited gene expression
driven by the WT (wild-type) SQSTM1-promoter but not
the mutant containing a defective AP-1 response-element
(Figure 3f). Thus, JunB suppresses SQSTM1 expression via
the AP-1 cis element.
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Figure 3. Chromatin immunoprecipitation (ChIP)-seq identifies p62/SQSTM1 as a JunB-target gene. (a) Percent of ChIP-seq distribution. (b) Motif analysis with
ChIPseeqerFire. (c) A representative ChIP-seq peak located on SQSTM1. (d) DNA sequence of the SQSTM1-promoter (Promoter ID: 33839; http://rulai.cshl.edu/
cgi-bin/TRED). The consensus AP-1 element —5’TGACTCA3’—was underlined in red. (e) ChIP–PCR with primers marked in (d). Graph represents the average fold
enrichment of triplicate samples by JunB ChIP over the input DNAþ SD. (f) Dual luciferase gene reporter analysis of 293T cells transfected with the firefly
luciferase reporter constructs containing the WT (wild-type) SQSTM1-promoter or the mutant with a defective AP-1 element along with the cytomegalovirus
(CMV)-renilla luciferase and JunB expression constructs. Graph represents the average of relative luciferase reading unitsþ SD.
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SQSTM1 mediates chemokine expression
Interestingly, among the JunB-responsive genes, only 27 of
them were enriched by JunB ChIP-seq (Supplementary Table
S3 online), which suggests that some of those responsive genes
were caused by secondary effects. Specifically, we predicted
that SQSTM1 is involved in mediating the upregulation of the
inflammatory cytokines. To test this idea, we first confirmed
that SQSTM1 was increased at the protein level by JunB gene
silencing (Figure 4a). We then performed gene silencing or
retrovirally mediated overexpression of exogenous SQSTM1
(Figure 4b–c). Quantitative RT–PCR revealed that exogenous
expression of SQSTM1 increased CXCL10 and CCL2 mRNA
levels as compared with LacZ control (Figure 4d). Conversely,
gene silencing of SQSTM1 prevented the induction of both
chemokines by reduced JunB expression (Figure 4e). These
results indicate that SQSTM1 positively regulates chemokine
expression.
NF-jB is required for the induction of CCL2 and CXCL10
As SQSTM1 is a key mediator of NF-kB activation by TRAF6/
IKKg signaling axis (Wooten et al., 2005; Zotti et al., 2014),
we predicted that NF-kB is responsible for the increased
cytokine expression. In agreement with this possibility, NF-
kB activation was induced by gene silencing of JunB as
indicated by the increased levels of pIKKa/b and pIkBa and
NF-kB-driven luciferase expression (Figure 5a–b). Inhibition of
NF-kB via the expression of the IkBa mutant (IkBaM), a well-
known super-repressor of NF-kB, abolished the induction of
CXCL10 by SQSTM1 (Figure 5c). To further test whether
NF-kB is required for the cytokine expression, we treated cells
with the pharmacological NF-kB inhibitor pyrrolidine dithio-
carbamate or autophagy inhibitor chloroquine at 24 hours post
gene silencing. The conditioned culture media were collected
for cytokine analyses at the 72 hours time point. We found that
pyrrolidine dithiocarbamate but not chloroquine markedly
reduced the protein levels of CCL2 and CXCL10 (Figure 5d).
In line with the results obtained with the pharmacological
agents, the expression of IkBaM significantly reduced the
mRNA levels of TNFa, CCL2, and CXCL10, as shown by
quantitative RT–PCR (Figure 5e). In contrast, IL6R, a direct
target of JunB which was previously validated in mouse kera-
tinocytes (Zenz et al., 2005), was not affected by IkBaM. In
agreement with the responsiveness to NF-kB, TNFa, CCL2,
and CXCL10, but not IL6R, all contained one or more putative
NF-kB cis elements on the promoter region (Supplementary
Figure S3 online). These findings indicate that NF-kB is
required for the induction of the proinflammatory cytokines.
Taken together, our findings support a working model in
which JunB-hypofunction leads to increased expression of
SQSTM1 and consequent NF-kB-dependent induction of
proinflammatory cytokines (Figure 6). In addition, JunB loss
of function increases cell proliferation and compromises
barrier functions through direct and indirect target gene
regulations. Future studies are needed to determine whether
the proinflammatory cytokines indirectly affect cell growth
and barrier function.
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DISCUSSION
Our studies demonstrate that reduced JunB expression affects
multiple cellular processes through direct and indirect regula-
tion of an array of target genes. The most pronounced
consequences of JunB reduction are the increased expression
of various proinflammatory chemokines and reduced
expression of cell adhesion molecules. SQSTM1, as a direct
downstream target of JunB, serves as a critical mediator to the
uncontrolled NF-kB activation and subsequent proinflamma-
tory responses.
Our findings suggest that the reduced JunB protein expres-
sion in psoriatic lesions, as demonstrated in earlier studies
(Zenz et al., 2005; Park et al., 2009), may contribute to the
development of lesions because of the uncontrolled expres-
sion of the inflammatory cytokines. In this respect, JunB may
be important for the inhibition of the disease onset or
progression. Given that JunB mRNA level is increased in
psoriatic lesions (Johansen et al., 2004; Kulski et al., 2005;
Haider et al., 2006), it is conceivable that the reduced JunB
protein level in the lesional skin is due to a posttranscriptional
deregulation. Future studies will be necessary to determine
whether and how JunB protein translation or stability is altered
in psoriatic lesions.
Current therapies for psoriasis are mainly focused on
targeting T-cell-mediated disease processes (Belge et al.,
2014). A chosen treatment option may produce good out-
comes for some patients but be less efficient for others, which
is likely due to the complex nature of the etiology involving
genetic and environmental heterogeneities. Our findings
suggest that it might be possible to block the disease at an
early stage by interfering keratinocyte-mediated proinflamma-
tory responses. Strategies that modulate the SQSTM1/NF-kB
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Figure 6. Working model: JunB suppression of inflammation. JunB regulates
epidermal cell proliferation, cell adhesion, and inflammation through direct
and indirect target genes. In particular, JunB-hypofunction leads to increased
expression of SQSTM1 and consequently NF-kB (nuclear factor kappa-light-
chain-enhancer of activated B cells)-dependent expression of multiple
inflammatory cytokines.
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signaling axis in keratinocytes might be applied for disease
prevention.
SQSTM1 is implicated in cancers of various organs, includ-
ing kidney (Li et al., 2013), tuberous sclerosis complex
(Parkhitko et al., 2011), pancreatic (Ling et al., 2012), pro-
state (Chang et al., 2014), lung (Inoue et al., 2012), and oral
(Inui et al., 2013; Kuo et al., 2014). However, in cutaneous
squamous cell carcinoma, SQSTM1 displays an inverse
correlation with malignant progression (Yoshihara et al.,
2014), suggesting that SQSTM1 may have epidermis-specific
functions. Similar to SQSTM1, NF-kB is known to stimulate
inflammation and tumorigenesis in a wide range of tissues. On
the other hand, persistent NF-kB activation promotes epider-
mal aging and inhibits cutaneous neoplasia (Dajee et al.,
2003; Zhang et al., 2004; Zhang et al., 2005b; Adler et al.,
2007). Thus, NF-kB-inhibition predicts both beneficial and
harmful results (Wullaert et al., 2011). It will be important to
determine whether SQSTM1 is involved in the regulation of
the functional dichotomy of NF-kB and may be exploited to
maximize the beneficial effects of NF-kB-targeted therapy.
MATERIALS AND METHODS
Cell culture, gene transfection, and barrier function analysis
Primary human keratinocytes were isolated from surgically discarded
foreskin samples obtained from Duke Children’s Hospital in accor-
dance to in institutionally approved IRB protocol. Patient consent for
experiments was not required because Federal Regulation considers
collection of surgically discarded and deidentified human tissues
poses minimal risk to human subjects. Cells were grown and
passaged in keratinocyte serum-free media (Invitrogen, Grand Island,
NY) at 37 1C with 5% CO2 and used at passage 2–3. A total of 293
T cells were obtained from ATCC and cultured in 10% fetal bovine
serum/DMEM. Gene transfection was performed with Genjet trans-
fection reagent (SignaGen Laboratories, Rockville, MD). Small inter-
fering RNA oligonucleotides targeting JunB (S7661 and S7662),
SQSTM1 (HSS113116), and non-silencing control were purchased
from Invitrogen and used at 100 nM concentrations. Unless noted,
siJunB were performed with S7661. The SQSTM1 complementary
DNA expression construct was obtained from Addgene (Cambridge,
MA) (Fan et al., 2010) and subcloned into the LZRS retroviral
construct. For barrier function analysis, cells were seeded onto to
Costar Transwell Permeable membrane inserts at 24 hours post
transfection and induced with 1.2 mM calcium for 24 and 48 hours.
TER was measured by using a Millipore Millicell ERS-2 ohm meter
(Billerica, MA). Readings were normalized against wells with no cells
(set as 0 resistance) and to insert area. A higher resistance indicates
better barrier function. The retroviral LZRS expression constructs for
JunB and DNJunB were described previously (Jin et al., 2011).
RNA-Seq and RT–PCR
For RNA-seq, total RNA was isolated from triplicate sets of human
keratinocytes at 48 hours after transfection using RNAeasy column
purification (Qiagen, Germantown, MD). Complementary DNA
library was prepared via oligo-dT-directed reverse transcription
(Ambion, Grand Island, NY), subjected to deep sequencing on
Illumina HiSeq 2000 (50-bp single-read sequencing), and analyzed
at Duke Genome Sequencing & Analysis Resource. The analysis
pipeline includes the initial QC to remove sequencing adaptors and
low-quality bases to facilitate mapping using fastx toolkit (http://
hannonlab.cshl.edu/fastx_toolkit/index.html). High-quality reads were
mapped to the human reference genome (hg19) using tophat
(Trapnell et al., 2009). The gene differential expression analysis was
performed between control and treatment using cuffdiff with upper
quartile normalization, multi-hit correction, and 0.5% false discovery
rate (Trapnell et al., 2013). Three biological replicates were used for
statistical analysis of differential expression for each comparison.
Pathway analyses were performed using WEB-based GEne SeT
AnaLysis Toolkit (Zhang et al., 2005a; Wang et al., 2013). SYBR
green-based real-time RT–PCR was performed in Bio-Rad iCycler
(Bio-Rad, Hercules, CA) with primers listed in (Supplementary Table
S4 online). Ribosomal 18S RNA or GAPDH (glyceraldehyde 3-
phosphate dehydrogenase) was used as an internal control.
ChIP-Seq and ChIP–PCR
ChIP was performed as described (Guo et al., 2012). In brief, primary
keratinocytes cultured in eight 30-cm plates were scraped off the dish
with phosphate-buffered saline at about 60–80% confluence, and
cross-linked with 1% formaldehyde for 8 minutes, and then treated
with 1.25 m glycine for 5 minutes to stop cross-link. Cells were
pelleted by centrifuging 5 minutes at 1,500 r.p.m. and lysed with ChIP
lysis buffer (Santa Cruz Biotechnology, Santa CruZ, CA) for cell nuclei
isolation. DNA fragmentation was performed by sonication with
Branson Sonifier (Fisher Scientific, Waltham, MA). The fragmented
DNA underwent IP with the antibody against JunB (Cell Signaling
Technology, Beverly, MA) followed by purification with the MinElute
DNA kit (Qiagen) and library construction with the NEBNext DNA
library preparation kit (New England BioLabs, Ipswich, MA). The
library was sequenced using Illumina Hiseq 2000 platform (San
Diego, CA) and analyzed at Duke Genome Sequencing & Analysis
Resource. The analysis pipeline includes the initial QC to remove
sequencing adaptors and low-quality bases to facilitate mapping
using fastx toolkit (Martin, 2011). High-quality reads were mapped
to the human reference genome (hg19) using bwa (Li and Durbin,
2009), and genes lists were from the Ensemble Gene database (http://
www.ensemble.org) and the RefSeq (www.ncbi.nlm.nih.gov/RefSeq).
Distal promoter and terminator regions of the genes were defined as
those sequences that mapped ±2kb upstream or ±50 kb from
transcription ‘‘start’’ and ‘‘end’’ sites, respectively. Peak detection,
annotation, de novo motif discovery, and pathway analysis were
performed using ChIPseeqer tool (Giannopoulou and Elemento, 2011)
and visualized by UCSC genome browser (Kent et al., 2002). Motif
analysis was performed with FIRESeq as described (Mathelier and
Wasserman, 2013). ChIP–PCR was performed with primers listed in
(Supplementary Table S4 online). The raw data and additional
information of ChIP-seq and RNA-seq are available from NCBI Gene
Expression Omnibus (Accession number GSE63081).
Multiplex cytokine analysis
For cytokine analysis, human keratinocytes cultured in 12-well plates
were transfected in duplicates with 100 nM small interfering RNA
oligonucleotides targeting non-silencing control and JunB (Invitro-
gen). At 24 hours post transfection, cells were treated with DMSO
control, pyrrolidine dithiocarbamate, or chloroquine (Sigma, St Louis,
MO) for 48 hours. Cell culture conditioned media were analyzed in
tetrads with the custom ordered Luminex Screening Assay System
(R&D Systems, Pittsburgh, PA). The readings were obtained on a
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Bioplex reader-200 (Bio-Rad) at a flow rate of 60ml min 1 and 50ml
per sample.
Skin regeneration
Human skin regeneration was performed as described in our previous
studies in accordance with the protocols approved by the Duke
Animal Care and Use Committee (Jin et al., 2011). In brief, primary
human keratinocytes were transduced with retrovirus encoding genes
of interest and seeded onto devitalized human cadaver dermis
(National Disease Research Institute) for grafting onto the back of
CB17.severe combined immunodeficient mice (n¼ 3–5 per group,
purchased from National Cancer Institute). Animals were euthanized
at 6 weeks post grafting for tissue collection.
Western blotting and immunostaining
For western blotting, 20mg protein lysates of primary human keratino-
cytes collected at 48–72hours post transfection were separated on SDS–
PAGE and immunobloted with antibodies against JunB, SQSTM1, IkBa,
and actin, followed by IR-dye-conjugated secondary antibodies (Invitro-
gen). The blots were scanned on the Odyssey imaging system (Li-COR,
Lincoln, NE). For immunostaining, 5-mm frozen tissue sections were
fixed with cold methanol, incubated with primary antibodies against Ki-
67, and detected with a secondary antibody conjugated to Alexa 5
(Invitrogen) and counterstaining with Hoechst 33342. The images were
obtained with the Olympus imaging system (Center Valley, PA).
Gene reporter analysis
NF-kB-luciferase (Promega, Madison, WI) and SQSTM1-luciferase
reporter constructs were transfected together with the cytomegalo-
virus-renilla luciferase and genes of interest into 293T cells using
Genjet transfection reagent. Dual luciferase assay was performed at
24 hours post transfection. The relative luciferase reading unit was
obtained by normalizing the readings of firefly luciferase to that of
renilla luciferase and then to that of the control cells. The P-values
were obtained in Excel with a two-tiered Student’s t-test.
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